Table 1.
Baseline clinical characteristics of Silent Infarct Transfusion (SIT) Trial and external validation cohort
| SIT Trial | WashU Cohort | P value* | ||
|---|---|---|---|---|
|
|
||||
| Training dataset (N=833) | Optimization dataset (N=93) | External validation (N=80) | ||
| Median (IQR) or N (%) | Median (IQR) or N (%) | Median (IQR) or N (%) | ||
|
| ||||
| Age, y | 8.8 (6.8, 10.9) | 9.4 (7.1, 11.9) | 11.5 (8.3, 19) | <0.001 |
| Male, N (%) | 417 (50) | 49 (43) | 40 (50) | 1.0 |
| African American, N (%) | 788 (94.6) | 86 (92.5) | 80 (100) | 0.03 |
| Hemoglobin, g/dl | 8 (7.4, 8.9) | 8 (7.5, 8.7) | 8.4 (7.7, 9.5) | 0.002 |
| Hemoglobin F, % | 10 (6, 17) | 11 (5, 16) | 9.2 (3.2, 21.4) | 0.46 |
| Hemoglobin S, % | 84 (78, 89) | 85 (77, 88) | 74 (59.4, 84.0) | <0.001 |
| White blood cell, 106/μL | 12 (10, 14.8) | 12.9 (10, 14.7) | 10.5 (8.2, 13.0) | <0.001 |
| SpO2, % | 97 (95, 99) | 96 (94, 98) | 98 (95, 99) | 0.32 |
| Systolic blood pressure, mmHg | 108 (101, 115) | 107 (101, 114) | 116 (110, 122) | <0.001 |
| SCI present, N (%) | 258 (31) | 29 (31) | 40 (50) | <0.001 |
| SCI volume, mL | 0 (0, 0.13) | 0 (0, 0.23) | 0.01 (0, 0.25) | 0.005 |
| SCI volume, within participants with SCI, mL | 0.40 (0.18, 1.00) | 0.42 (0.29, 2.32) | 0.25 (0.13, 0.72) | 0.03 |
Abbreviations: SIT, Silent Infarction Transfusion; SCI, silent cerebral infarct; SpO2, peripheral oxygen saturation
*
Comparison between the SIT Trial cohort and the external validation cohort